Urate-Lowering Therapy Linked to Reduced Kidney Disease Progression and Mortality in CKD

Urate-lowering therapy (ULT) is associated with a significantly lower risk of kidney disease progression and mortality in patients with chronic kidney disease (CKD) and hyperuricemia, according to recent research.

A cohort study using a sequential target trial emulation framework evaluated kidney outcomes in patients with CKD and hyperuricemia who initiated ULT versus those receiving supportive care alone. The study included 269,831 eligible person trials from 56,936 unique individuals drawn from the China Renal Data System database.

The primary outcome was a composite kidney endpoint defined as a greater than 40% decline in estimated glomerular filtration rate (eGFR) or progression to end-stage kidney disease (ESKD). Over a three-year follow-up period, the cumulative incidence of this composite outcome was 19.69% in the ULT group compared to 23.22% in the control group, representing a risk difference of −3.53% (95% confidence interval: −5.25% to −1.94%).

Further analysis revealed that ULT was linked to reduced risks across multiple critical outcomes. The estimated three-year risk difference for ESKD was −1.88% (95% CI: −3.28% to −0.45%), for all-cause mortality it was −2.25% (95% CI: −3.02% to −1.51%), and for cardiovascular mortality it was −0.69% (95% CI: −1.33% to −0.05%), all favoring the ULT group.

Subgroup and sensitivity analyses produced results consistent with the primary analysis, reinforcing the robustness of the findings. Researchers concluded that ULT is associated with a significantly lower risk of kidney disease progression and mortality specifically in patients with stage 3 or higher CKD and hyperuricemia.

These findings support the growing recognition of hyperuricemia as a modifiable risk factor in CKD progression. While the study provides strong observational evidence, experts note that large randomized clinical trials with refined designs are still needed to definitively establish the causal effect of ULT on kidney outcomes in this population.

The research contributes to an evolving body of evidence examining the role of urate management in renal health, building upon prior systematic reviews and meta-analyses that have explored the potential benefits of urate-lowering approaches in patients with moderate to severe CKD.